| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.0092 | 0.9 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | PD-0332991 | FIMM | pan-cancer | AAC | 0.019 | 0.9 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |